Payment overview · 2025
General Payments
$520.07
26 reported records · 13 companies
Healthcare provider profile · identity verified
Jose Xavier Pluguez, MD
Allopathic & Osteopathic Physicians|General Practice · DAVENPORT, FL · NPI 1922158476
Verified facts
What the public records show
CMS Open Payments records show Jose Xavier Pluguez, MD received $520.07 in general payments during 2025 across 26 reported records.
Novo Nordisk Inc accounted for 24.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $124.75 | 24.0% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $59.57 | 11.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $54.90 | 10.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.17 | 9.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.94 | 9.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.33 | 8.9% | 3 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $33.94 | 6.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.86 | 4.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.90 | 3.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.87 | 3.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.89 | 2.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.60 | 2.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.35 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $520.07 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.55 | 4 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $59.57 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $54.90 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.54 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.17 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $46.94 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.33 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.33 | 3 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $33.94 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $33.94 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.19 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 34 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 44 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 315 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 189 | 74 |
| Lisinopril | Lisinopril | 180 | 61 |
| Metformin Hcl | Metformin Hcl | 178 | 59 |
| Losartan Potassium | Losartan Potassium | 162 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 118 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 44 |
| Omeprazole | Omeprazole | 109 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 38 |
| Gabapentin | Gabapentin | 103 | 36 |
| Montelukast Sodium | Montelukast Sodium | 95 | 38 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 90 | 39 |
| Simvastatin | Simvastatin | 84 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 32 |
| Famotidine | Famotidine | 74 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 66 | 25 |
| Furosemide | Furosemide | 60 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 60 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 32 |
| Alendronate Sodium | Alendronate Sodium | 47 | 18 |
| Allopurinol | Allopurinol | 45 | 19 |
| Jardiance | Empagliflozin | 44 | 17 |
| Ibuprofen | Ibuprofen | 41 | 18 |
| Glimepiride | Glimepiride | 40 | suppressed |
| Meloxicam | Meloxicam | 40 | 18 |
| Ezetimibe | Ezetimibe | 39 | 15 |
| Carvedilol | Carvedilol | 38 | 14 |
| Methylprednisolone | Methylprednisolone | 37 | 36 |
| Glipizide Er | Glipizide | 35 | 17 |
| Eliquis | Apixaban | 34 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | 12 |
| Glipizide | Glipizide | 31 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 18 |
| Tramadol Hcl | Tramadol Hcl | 31 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 30 |
| Clonazepam | Clonazepam | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | 11 |
| Atenolol | Atenolol | 28 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 16 |
| Trazodone Hcl | Trazodone Hcl | 25 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 24 |
| Finasteride | Finasteride | 24 | suppressed |
| Prednisone | Prednisone | 24 | 22 |
| Sildenafil Citrate | Sildenafil Citrate | 24 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | 11 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 12 |
| Cephalexin | Cephalexin | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $520.07 · 26 records | Novo Nordisk Inc | AIRSUPRA, APTIMA, AREXVY, ELIQUIS, FREESTYLE LIBRE 3, General - Therapies, JARDIANCE, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, THINPREP 2000 PROCESSOR, VOQUEZNA, Wegovy, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error